Acadia Pharmaceuticals
ACAD
187 hedge funds and large institutions have $1.79B invested in Acadia Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 41 funds opening new positions, 63 increasing their positions, 59 reducing their positions, and 49 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
19% more call options, than puts
Call options by funds: $47.2M | Put options by funds: $39.6M
7% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 59
4.31% less ownership
Funds ownership: 97.96% → 93.65% (-4.3%)
5% less funds holding
Funds holding: 196 → 187 (-9)
16% less first-time investments, than exits
New positions opened: 41 | Existing positions closed: 49
35% less capital invested
Capital invested by funds: $2.74B → $1.79B (-$960M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$55M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$35.7M |
| 3 |
State Street
Boston,
Massachusetts
|
+$29.4M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$16.9M |
| 5 |
O
OrbiMed
New York
|
+$16.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
-$72.7M |
| 2 |
Janus Henderson Group
London,
|
-$63.2M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$48.7M |
| 4 |
HM
HealthCor Management
New York
|
-$31M |
| 5 |
JP Morgan Chase
New York
|
-$25.5M |
ACAD Hedge Fund Activity: Q2 2018 in Review
187 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Acadia Pharmaceuticals (ACAD) for Q2 2018, worth a combined $1.79B — down 35% from $2.74B a quarter earlier.
Sellers outnumbered buyers: 49 funds closed out of ACAD and 41 opened new positions — a net loss of 8 holders — while 59 trimmed existing stakes and 63 added.
The largest buyer was BlackRock, adding an estimated $55M. The largest seller was Capital World Investors, cutting an estimated $72.7M.
- 187 institutional investors held Acadia Pharmaceuticals (ACAD) as of Q2 2018, down from 196 in Q1 2018.
- Funds reported $1.79B of Acadia Pharmaceuticals stock for Q2 2018, down 35% quarter-over-quarter.
- 41 funds opened new Acadia Pharmaceuticals positions in Q2 2018 and 49 closed out, a net change of -8 holders.
- The largest Acadia Pharmaceuticals buyer in Q2 2018 was BlackRock, an estimated $55M added.
- The largest Acadia Pharmaceuticals seller in Q2 2018 was Capital World Investors, an estimated $72.7M sold.
Based on aggregated 13F filings for Q2 2018.